Methotrexate Market Outlook:
Methotrexate Market size was valued at USD 1.19 billion in 2025 and is likely to cross USD 1.88 billion by 2035, expanding at more than 4.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of methotrexate is assessed at USD 1.24 billion.
The rising prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is augmenting the consumption of methotrexate solutions. For instance, according to the National Psoriasis Foundation, millions of people across the world are living with psoriatic arthritis, and around 2% to 3% of the total population have psoriasis. The report by the Global Psoriasis Atlas reveals that an estimated 60 million individuals are living with psoriasis, globally. Furthermore, the Global RA Network reveals that around 350 million people worldwide are living with arthritis issues. 1 in 100 people often are diagnosed with rheumatoid arthritis and if not treated are leading to work disability.
For instance, in January 2024, Novartis AG one of the leading manufacturers of methotrexate solutions revealed that its robust operational performance led to huge double-digit top and bottom-line growth. The company estimates 40.0%+ margin growth by 2027 and 5.0% cc CAGR between 2023 and 2028. Furthermore, the net sales increased by +10.0% with core operating income growth of +18.0%. Cardiovascular-renal-metabolic, immunology, neuroscience, and oncology are four core therapeutic areas driving the company’s growth.
